E130012A19Rik Activators
Epop, an elongin BC and polycomb repressive complex 2 associated protein, plays a pivotal role in chromatin dynamics, histone modification, and transcriptional regulation. Its known functions include chromatin binding activity, histone H2B conserved C-terminal lysine deubiquitination, regulation of transcription by RNA polymerase II, and involvement in stem cell differentiation. Furthermore, Epop acts upstream of or within neuron fate commitment, highlighting its significance in cellular processes related to neurogenesis. The activation of Epop is intricately linked to various cellular mechanisms and pathways. The involvement of Epop in the ESC/E(Z) complex and elongin complex suggests its critical role in epigenetic regulation. The chemicals outlined in the table modulate pathways influencing Epop directly or indirectly, impacting its function in chromatin binding and transcriptional regulation. Trichostatin A and SAHA, as histone deacetylase inhibitors, enhance Epop's chromatin binding activity by promoting chromatin accessibility. JQ1, a BET inhibitor, indirectly influences Epop by altering BRD4-mediated processes, indicating a connection between BRD4 and Epop's role in stem cell differentiation. Proteasome inhibitor MG132 disrupts protein degradation, indirectly up-regulating Epop, possibly through post-translational regulation mechanisms.
Epigenetic modulators like 5-Azacytidine and Vitamin C indirectly promote Epop's function by altering DNA methylation and influencing histone demethylases, respectively. Specific inhibitors of histone demethylases (Lysine Demethylase Inhibitor II, SP2509) and methyltransferases (BIX-01294, 3-Deazaneplanocin A, UNC1999, EPZ005687) modulate histone methylation patterns, potentially impacting Epop's chromatin dynamics and its involvement in stem cell differentiation. Overall, the interconnected nature of these chemicals and their influence on key cellular processes underscore the complexity of Epop activation and its crucial role in orchestrating epigenetic regulation. Further research is warranted to unravel the precise molecular mechanisms and regulatory networks governing Epop's function in chromatin dynamics and cellular differentiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, modulates chromatin structure. This epigenetic change enhances Epop's chromatin binding activity, directly impacting its role in the ESC/E(Z) complex. The inhibition of HDACs promotes chromatin accessibility, potentially influencing the regulation of transcription. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET inhibitor, downregulates BRD4. Reduced BRD4 levels affect transcriptional regulation, indirectly influencing Epop's activity within the ESC/E(Z) complex. This BET inhibition alters the recruitment of Epop to chromatin, suggesting a link between BRD4-mediated processes and Epop's role in stem cell differentiation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132, a proteasome inhibitor, disrupts protein degradation pathways. The inhibition of proteasomes indirectly up-regulates Epop by preventing its degradation, highlighting a potential post-translational regulation mechanism. This disruption may enhance Epop's involvement in histone H2B deubiquitination and RNA polymerase II regulation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, alters DNA methylation patterns. This epigenetic change indirectly promotes Epop's function in chromatin binding and transcriptional regulation. The disruption of DNA methylation dynamics may enhance Epop's involvement in stem cell differentiation and neuronal fate commitment. | ||||||
L-Ascorbic acid, free acid | 50-81-7 | sc-202686 | 100 g | $46.00 | 5 | |
L-Ascorbic acid, free acid influences the activity of Jumonji domain-containing histone demethylases. The modulation of these demethylases may indirectly affect Epop's function in histone H2B deubiquitination and RNA polymerase II regulation. This suggests a potential link between cellular metabolism, vitamin C availability, and Epop-mediated chromatin dynamics. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509, a specific inhibitor of the lysine demethylase LSD1, affects histone methylation dynamics. Inhibition of LSD1 may indirectly enhance Epop's role in chromatin binding and transcriptional regulation, indicating a potential interplay between LSD1-mediated processes and Epop's function within the ESC/E(Z) complex. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
BIX-01294, a G9a histone methyltransferase inhibitor, modulates histone methylation patterns. The inhibition of G9a may indirectly up-regulate Epop by altering chromatin dynamics, potentially impacting the regulation of stem cell differentiation and neuron fate commitment processes. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999, a selective inhibitor of the histone methyltransferase G9a, modulates histone methylation patterns. Inhibition of G9a may indirectly enhance Epop's role in chromatin binding and transcriptional regulation, pointing to potential interactions between G9a-mediated processes and Epop's function within the ESC/E(Z) complex. | ||||||
EPZ005687 | 1396772-26-1 | sc-497734 | 2.5 mg | $380.00 | ||
EPZ005687, an EZH2 histone methyltransferase inhibitor, affects histone methylation dynamics. Inhibition of EZH2 may indirectly influence Epop's function within the ESC/E(Z) complex, suggesting a link between EZH2-mediated processes and Epop's involvement in histone H2B deubiquitination and transcriptional regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA, a histone deacetylase inhibitor, modulates chromatin structure. This epigenetic change enhances Epop's chromatin binding activity, directly impacting its role in the ESC/E(Z) complex. Inhibition of HDACs promotes chromatin accessibility, potentially influencing the regulation of transcription, stem cell differentiation, and neuron fate commitment. | ||||||